The risk of hypoglycemia in T2D patients was additionally evaluated in a meta-analysis of 5 confirmatory trials (3582, 3579, 3672, 3586, 3668) that considered the subset of subjects who required high basal insulin doses (>60 U) at the end of the studies (n = 795 patients receiving IDeg versus n = 374 receiving IGlar for 26 or 52 weeks). This evidence concerns the gene INS and Hypoglycemia.